Art

J-GLOBAL ID：201802276332954581   Reference number：18A0135317

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study

進行NSCLC(SWOGS0819)のベバシズマブのないベバシズマブvs.カルボプラチンとパクリタキセルを伴うまたは伴わないセツキシマブ+カルボプラチンとパクリタキセル:無作為化第3相試験【Powered by NICT】

Author (18)： Herbst Roy S (Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ,  Redman Mary W (Southwest Oncology Group (SWOG) Statistical Center and Clinical Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, WA, USA) ,  Kim Edward S (Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA) ,  Semrad Thomas J (University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA) ,  Bazhenova Lyudmila (Moores Cancer Center, University of California, San Diego, San Diego, CA, USA) ,  Masters Gregory (Christiana Care Health Systems, Helen F Graham Cancer Center and Research Institute, Wilmington, DE, USA) ,  Oettel Kurt (Wisconsin National Cancer Institute Community Oncology Research Program (NCORP), Gundersen Health System, LaCrosse, WI, USA) ,  Guaglianone Perry (Heartland Cancer Research NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL, USA) ,  Reynolds Christopher (Michigan Cancer Research Consortium NCORP, St Joseph Mercy Health System, Ann Arbor, MI, USA) ,  Karnad Anand (University of Texas Health Science Center at San Antonio, San Antonio, TX, USA) ,  Arnold Susanne M (Markey Cancer Center, University of Kentucky, Lexington, KY, USA) ,  Varella-Garcia Marileila (Department of Medicine, Division of Medical Oncology, University of Colorado, Aurora, CO, USA) ,  Moon James (Southwest Oncology Group (SWOG) Statistical Center and Clinical Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, WA, USA) ,  Mack Philip C (University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA) ,  Blanke Charles D (SWOG Group Chair’s Office, Oregon Health & Science University, Portland, OR, USA) ,  Hirsch Fred R (Department of Medicine, Division of Medical Oncology, University of Colorado, Aurora, CO, USA) ,  Kelly Karen (University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA) ,  Gandara David R (University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA)
Material： Lancet Oncology  (Lancet Oncol)
Volume： 19  Issue： 1  Page： 101-114  Publication year： 2018 
JST Material Number： W1266A  ISSN： 1470-2045  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： EGFR antibodies have shown pro...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0135317&from=J-GLOBAL&jstjournalNo=W1266A") }}

Thesaurus term： *non-small cell lung cancer ,  squamous cell carcinoma ,  EGF receptor ,  patient ,  drug therapy ,  United States of America ,  Safety ,  *phase 3 study ,  survival ratio ,  FISH ,  *platinum complex ,  *antitumor drug ,  diterpene ,  oxygen heterocyclic compound ,  bridged compound
Semi thesaurus term： *carboplatin ,  無増悪生存期間 ,  *セツキシマブ ,  *ベバシズマブ , 【Automatic Indexing@JST】

JST classification (1)： Treatment for tumors in general  (GE03031L)

Substance index (1)： Paclitaxel

Terms in the title (7)： NSCLC ,  ベバシズマブ ,  Vs ,  カルボプラチン ,  パクリタキセル ,  セツキシマブ ,  第3相試験